Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring (Q34619064)

3 August 2017

1 reference

title

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring (English)

1 reference

3 August 2017

0 references

1 reference

3

Hans-Peter Hartung

1 reference

3 August 2017

1

Ludwig Kappos

1 reference

3 August 2017

10

Howard L Weiner

1 reference

3 August 2017

5

David Miller

1 reference

3 August 2017

8

Stephen L Hauser

1 reference

3 August 2017

6

Chris H Polman

1 reference

3 August 2017

7

Mads Ravnborg

1 reference

3 August 2017

David Bates

2

1 reference

3 August 2017

Eva Havrdova

4

1 reference

3 August 2017

Richard A Rudick

9

1 reference

3 August 2017

Paul W O'Connor

11

1 reference

3 August 2017

John King

12

1 reference

3 August 2017

Ernst Wilhelm Radue

13

1 reference

3 August 2017

Tarek Yousry

14

1 reference

3 August 2017

Eugene O Major

15

1 reference

3 August 2017

David B Clifford

16

1 reference

3 August 2017

publication date

1 May 2007

1 reference

3 August 2017

1 reference

3 August 2017

volume

6

1 reference

3 August 2017

issue

5

1 reference

3 August 2017

page(s)

431-441

1 reference

How many people in the world have multiple sclerosis?

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

The adhesion molecule and cytokine profile of multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Pathogenesis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Anti-alpha4 integrin antibody induces apoptosis in murine thymocytes and staphylococcal enterotoxin B-activated lymph node T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

New insights into progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Comparison of cell culture-grown JC virus (primary human fetal glial cells and the JCI cell line) and recombinant JCV VP1 as antigen for the detection of anti-JCV antibody by haemagglutination inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Neurologic disease as the presenting manifestation of acquired immunodeficiency syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Neurotoxicity and Elevated Cerebrospinal-Fluid Methotrexate Concentration in Meningeal Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Progressive multifocal leukoencephalopathy: immunofluorescent demonstration of simian virus 40 antigen in CSF cells and response to cytarabine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Case Report Simultaneous fungal and viral infection of the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Successful outcome of progressive multifocal leukoencephalopathy in a renal transplant patient

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Progressive multifocal leukoencephalopathy in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Progressive multifocal leukoencephalopathy and cryptococcal meningitis with systemic lupus erythematosus and thymoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Visual symptoms after lung transplantation: a case of progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Progressive multifocal leukoencephalopathy in transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Unsuccessful treatment with cidofovir and cytarabine in progressive multifocal leukoencephalopathy associated with dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Progressive multifocal leucoencephalopathy isolated to the posterior fossa in a patient with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Detection of human herpesvirus 6 and JC virus in progressive multifocal leukoencephalopathy complicating follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

1 reference

7 January 2021

Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Progressive multifocal leukoencephalopathy presenting as a solitary gray matter lesion

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Cortical and subcortical JC virus infection: two unusual cases of AIDS associated progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Neuropathology of the spinal cord in the acquired immunodeficiency syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Progressive multifocal leukoencephalopathy in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Analysis of PCR as a tool for detection of JC virus DNA in cerebrospinal fluid for diagnosis of progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

JCV-DNA and BKV-DNA in the CNS tissue and CSF of AIDS patients and normal subjects. Study of 41 cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Infection of human polyomaviruses JC and BK in peripheral blood leukocytes from immunocompetent individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

BK and JC viruses in human immunodeficiency virus type 1-infected persons: prevalence, excretion, viremia, and viral regulatory regions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Genotype profile of human polyomavirus JC excreted in urine of immunocompetent individuals.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Detection of JC virus DNA in the peripheral blood leukocytes of HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Association of human polyomavirus JC with peripheral blood of immunoimpaired and healthy individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Immune response in progressive multifocal leukoencephalopathy: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Advances in the biology of JC virus and induction of progressive multifocal leukoencephalopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Opportunistic infections of the CNS in patients with AIDS: diagnosis and management

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Central nervous system infections in individuals with HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Viral infections of the nervous system, 2002: update on diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Immune surveillance in multiple sclerosis patients treated with natalizumab.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Natalizumab effects on immune cell responses in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Natalizumab: immune effects and implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Progressive multifocal leukoencephalopathy and human immunodeficiency virus-associated white matter lesions in AIDS: magnetization transfer MR imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

Identification of HIV-associated progressive multifocal leukoencephalopathy: magnetic resonance imaging and spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970078-9

7 January 2021

10.1016/S1474-4422(07)70078-9

Identifiers

DOI

1 reference

3 August 2017

1 reference